Skip to main content
. 2017 Mar 31;8(21):34836–34843. doi: 10.18632/oncotarget.16753

Figure 1.

Figure 1

PZ-ratio in PCa and biopsy-negative patients in all PCa of all patient group (A) and of patients with PSA of 4–10 ng/ml (B)significant PCa vs. insignificant PCa+ negative biopsy of all patient group (C) and patients with PSA of 4–10 ng/ml (D) and the relevance of PZ-ratio with age in all ages (E) and subdivided by age groups (F). PZ-ratio, peripheral zone volume ratio; PCa, prostate cancer; NBx, negative biopsy; Sig PCa, significant prostate cancer; nonsig PCa, non-significant prostate cancer.